Launched by Mount Sinai in 2022, CastleVax is a clinical-stage vaccine company developing intranasal vaccines with an attenuated Newcastle Disease Virus platform. Its lead candidate, CVAX-01, is a next-generation COVID-19 vaccine designed to stimulate mucosal as well as systemic immunity, while the same platform is being applied to additional respiratory and other infectious diseases. The company’s scientific roots trace to Mount Sinai researchers Peter Palese, Adolfo García-Sastre, Florian Krammer, and Weina Sun.
Transmucosis, LLCFounded by Dr. Herbert Heyneker and Dr. Xiaoping Zhu, Transmucosis develops protein-based nasal vaccines designed to activate both mucosal and systemic immunity. Its platform uses the human IgG Fc region and the FcRn receptor to transport vaccine molecules across respiratory epithelial barriers, with lead candidates focused on influenza and COVID-19. The company anticipates submitting investigational new drug applications for those candidates in the second half of 2026.CLARKSVILLE, MD
TechnoVax IncFounded in 2004, privately held TechnoVax is a New York metro-area biotechnology company developing viral vaccines through a cell-based virus-like particle platform. Its near-clinical-stage work centers on vaccine candidates for influenza and RSV, including an inhaled powder approach developed with a pulmonary drug-delivery partner. The company also provides biological products and collaborative research services for vaccine, diagnostic, and research applications.ELMSFORD, NY
NovavaxHeadquartered in Gaithersburg, Maryland, Novavax is a biotech company that develops vaccines and vaccine technologies, pairing protein-based nanoparticles with its proprietary Matrix-M® adjuvant. Its platform underpins marketed vaccines for COVID-19 and malaria, while the company continues in-house R&D and works with pharmaceutical, research and government partners to advance additional medicines. Novavax also conducts R&D and Matrix-M manufacturing in Uppsala, Sweden.GAITHERSBURG, MD
POP Biotechnologies, IncBuffalo-based POP Biotechnologies develops nanotechnology platforms for vaccines, immunotherapies and light-activated cancer drug delivery. Its patented SNAP technology forms nanoliposome vaccines by binding His-tagged antigens to CoPoP liposomes, and has supported EuCorVac-19, a COVID-19 vaccine that met primary endpoints in a Phase 3 study. The company also produces CoPoP under GMP at a 2.5-million-dose scale and is advancing PhotoDOX, which uses red light to trigger localized doxorubicin release in solid tumors.BUFFALO, NY